Pan-cancer analysis indicates that MYBL2 is associated with the prognosis and immunotherapy of multiple cancers as an oncogene

References

• Blum A, Wang P, Zenklusen JC. SnapShot: TCGA-analyzed tumors. Cell. 2018;173(2):530. Cited in: PubMed; PMID 29625059.
   PubMed Web of Science ®Google Scholar
• Tomczak K, Czerwińska P, Wiznerowicz M. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contemp Oncol (Pozn). 2015;19(1A):A68–77. Cited in: PubMed; PMID 25691825.
   PubMedGoogle Scholar
• Clough E, Barrett T. The gene expression omnibus database. Methods Mol Biol. 2016; 141893. Cited in: PubMed; PMID 27008011. DOI: https://doi.org/10.1007/978-1-4939-3578-9_5
   Google Scholar
• Oh IH, Reddy EP. The myb gene family in cell growth, differentiation and apoptosis. Oncogene. 1999;18(19):3017–3033. Cited in: PubMed; PMID 10378697.
   PubMed Web of Science ®Google Scholar
• Chayka O, Sala A. MYBL2 (v-myb myeloblastosis viral oncogene homolog (avian)-like 2). Atlas Genet Cytogenet OncolHaematol. 2011;(9). DOI:https://doi.org/10.4267/2042/44558.
   Google Scholar
• Lu S, Wang J, Chitsaz F, et al. CDD/SPARCLE: the conserved domain database in 2020. Nucleic Acids Res. 2020;48(D1):D265–D268. Cited in: PubMed; PMID 31777944.
   PubMed Web of Science ®Google Scholar
• Papetti M, Augenlicht LH. MYBL2, a link between proliferation and differentiation in maturing colon epithelial cells. J Cell Physiol. 2011;226(3):785–791. Cited in: PubMed; PMID 20857481.
   PubMed Web of Science ®Google Scholar
• Musa J, Aynaud -M-M, Mirabeau O, et al. MYBL2 (B-Myb): a central regulator of cell proliferation, cell survival and differentiation involved in tumorigenesis. Cell Death Dis. 2017;8(6):e2895. Cited in: PubMed; PMID 28640249.
   PubMedGoogle Scholar
• Mao X, Orchard G, Lillington DM, et al. Amplification and overexpression of JUNB is associated with primary cutaneous T-cell lymphomas. Blood. 2003;101(4):1513–1519. Cited in: PubMed; PMID 12393503.
   PubMed Web of Science ®Google Scholar
• Qi G, Zhang C, Ma H, et al. CDCA8, targeted by MYBL2, promotes malignant progression and olaparib insensitivity in ovarian cancer. Am J Cancer Res. 2021;11(2):389–415. Cited in: PubMed; PMID 33575078.
   PubMed Web of Science ®Google Scholar
• Guan Z, Cheng W, Huang D, et al. High MYBL2 expression and transcription regulatory activity is associated with poor overall survival in patients with hepatocellular carcinoma. Curr Res Transl Med. 2018;66(1):27–32. Cited in: PubMed; PMID 29274707.
   PubMed Web of Science ®Google Scholar
• Chen J, Chen X. MYBL2 is targeted by miR-143-3p and regulates breast cancer cell proliferation and apoptosis. Oncol Res. 2018;26(6):913–922. Cited in: PubMed; PMID 29268817.
   PubMed Web of Science ®Google Scholar
• Skotheim RI, Monni O, Mousses S, et al. New insights into testicular germ cell tumorigenesis from gene expression profiling. Cancer Res. 2002;62(8):2359–2364. Cited in: PubMed; PMID 11956097.
   PubMed Web of Science ®Google Scholar
• Li Q, Wang M, Hu Y, et al. MYBL2 disrupts the Hippo-YAP pathway and confers castration resistance and metastatic potential in prostate cancer. Theranostics. 2021;11(12):5794–5812. Cited in: PubMed; PMID 33897882.
   PubMed Web of Science ®Google Scholar
• Ahmed F. Integrated network analysis reveals FOXM1 and MYBL2 as key regulators of cell proliferation in non-small cell lung cancer. Front Oncol. 2019; 91011. Cited in: PubMed; PMID 31681566. DOI: https://doi.org/10.3389/fonc.2019.01011
   Google Scholar
• Bayley R, Ward C, Garcia P. MYBL2 amplification in breast cancer: molecular mechanisms and therapeutic potential. Biochim Biophys Acta Rev Cancer. 2020;1874(2):188407. Cited in: PubMed; PMID 32853735.
   PubMed Web of Science ®Google Scholar
• Li M, Liu Y, Liu J, et al. Circ_0006332 promotes growth and progression of bladder cancer by modulating MYBL2 expression via miR-143. Aging (Albany NY). 2019;11(22):10626–10643. Cited in: PubMed; PMID 31756170.
   PubMedGoogle Scholar
• Wei T, Weiler SME, Tóth M, et al. YAP-dependent induction of UHMK1 supports nuclear enrichment of the oncogene MYBL2 and proliferation in liver cancer cells. Oncogene. 2019;38(27):5541–5550. Cited in: PubMed; PMID 30936457.
   PubMed Web of Science ®Google Scholar
• Rhodes DR, Kalyana-Sundaram S, Mahavisno V, et al. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia. 2007;9(2):166–180. Cited in: PubMed; PMID 17356713.
   PubMed Web of Science ®Google Scholar
• Li T, Fan J, Wang B, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77(21):e108–e110. Cited in: PubMed; PMID 29092952.
   PubMed Web of Science ®Google Scholar
• Tang Z, Li C, Kang B, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98–W102. Cited in: PubMed; PMID 28407145.
   PubMed Web of Science ®Google Scholar
• Ru B, Wong CN, Tong Y, et al. TISIDB: an integrated repository portal for tumor-immune system interactions. Bioinformatics. 2019;35(20):4200–4202. Cited in: PubMed; PMID 30903160.
   PubMed Web of Science ®Google Scholar
• Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401–404. Cited in: PubMed; PMID 22588877.
   PubMed Web of Science ®Google Scholar
• Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269):l1. Cited in: PubMed; PMID 23550210.
   Web of Science ®Google Scholar
• Chandrashekar DS, Bashel B, Balasubramanya SAH, et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 2017;19(8):649–658. Cited in: PubMed; PMID 28732212.
   PubMed Web of Science ®Google Scholar
• Li Y, Di G, Lu C. The SMART App: an interactive web application for comprehensive DNA methylation analysis and visualization. Epigenetics Chromatin. 2019;12(1):71. Cited in: PubMed; PMID 31805986.
   PubMed Web of Science ®Google Scholar
• Koch A, Jeschke J, Van Criekinge W, et al. MEXPRESS update 2019. Nucleic Acids Res. 2019;47(W1):W561–W565. Cited in: PubMed; PMID 31114869.
   PubMed Web of Science ®Google Scholar
• Sturm G, Finotello F, List M. Immunedeconv: an R package for unified access to computational methods for estimating immune cell fractions from bulk RNA-sequencing data. Methods Mol Biol. 2020; 2120223–2120232. Cited in: PubMed; PMID 32124323. DOI: https://doi.org/10.1007/978-1-0716-0327-7_16
   Google Scholar
• Chalmers ZR, Connelly CF, Fabrizio D, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9(1):34. Cited in: PubMed; PMID 28420421.
   PubMed Web of Science ®Google Scholar
• Luchini C, Brosens LAA, Wood LD, et al. Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability: histology, molecular pathology and clinical implications. Gut. 2021;70(1):148–156. Cited in: PubMed; PMID 32350089.
   PubMed Web of Science ®Google Scholar
• Sahai E, Astsaturov I, Cukierman E, et al. A framework for advancing our understanding of cancer-associated fibroblasts. Nat Rev Cancer. 2020;20(3):174–186. Cited in: PubMed; PMID 31980749.
   PubMed Web of Science ®Google Scholar
• Fridman WH, Galon J, Dieu-Nosjean M-C, et al. Immune infiltration in human cancer: prognostic significance and disease control. Curr Top Microbiol Immunol. 2011; 3441. Cited in: PubMed; PMID 20512556. DOI: https://doi.org/10.1007/82_2010_46
   Google Scholar
• Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer. 2006;6(5):392–401. Cited in: PubMed; PMID 16572188.
   PubMed Web of Science ®Google Scholar
• Chen X, Song E. Turning foes to friends: targeting cancer-associated fibroblasts. Nat Rev Drug Discov. 2019;18(2):99–115. Cited in: PubMed; PMID 30470818.
   PubMed Web of Science ®Google Scholar
• Aran D, Hu Z, Butte AJ. xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol. 2017;18(1):220. Cited in: PubMed; PMID 29141660.
   PubMed Web of Science ®Google Scholar
• Li T, Fu J, Zeng Z, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020;48(W1):W509–W514. Cited in: PubMed; PMID 32442275.
   PubMed Web of Science ®Google Scholar
• Barroso-Sousa R, Barry WT, Garrido-Castro AC, et al. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol. 2018;4(2):173–182. Cited in: PubMed; PMID 28973656.
   PubMed Web of Science ®Google Scholar
• Wang J, Sun J, Liu LN, et al. Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy. Nat Med. 2019;25(4):656–666. Cited in: PubMed; PMID 30833750.
   PubMed Web of Science ®Google Scholar
• Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature. 2001;411(6835):342–348. Cited in: PubMed; PMID 11357141.
   PubMed Web of Science ®Google Scholar
• Williams GH, Stoeber K. The cell cycle and cancer. J Pathol. 2012;226(2):352–364. Cited in: PubMed; PMID 21990031
   PubMed Web of Science ®Google Scholar
• Wei T, Weiler SME, Tóth M, et al. YAP-dependent induction of UHMK1 supports nuclear enrichment of the oncogene MYBL2 and proliferation in liver cancer cells. Oncogene. 2019;38(27):5541–5550. Cited in: PubMed; PMID 30936457
   PubMed Web of Science ®Google Scholar
• Bayley R, Ward C, Garcia P. MYBL2 amplification in breast cancer: molecular mechanisms and therapeutic potential. Biochim Biophys Acta Rev Cancer. 2020;1874(2):188407. Cited in: PubMed; PMID 32853735.
   PubMed Web of Science ®Google Scholar
• Li Q, Wang M, Hu Y, et al. MYBL2 disrupts the Hippo-YAP pathway and confers castration resistance and metastatic potential in prostate cancer. Theranostics. 2021;11(12):5794–5812. Cited in: PubMed; PMID 33897882.
   PubMed Web of Science ®Google Scholar
• Jin Y, Zhu H, Cai W, et al. B-Myb is up-regulated and promotes cell growth and motility in non-small cell lung cancer. Int J Mol Sci. 2017;18(6): Cited in: PubMed; PMID 28555007. DOI:https://doi.org/10.3390/ijms18060860.
   Google Scholar
• Zhang X, Lv Q-L, Huang Y-T, et al. Akt/FoxM1 signaling pathway-mediated upregulation of MYBL2 promotes progression of human glioma. J Exp Clin Cancer Res. 2017;36(1):105. Cited in: PubMed; PMID 28784180.
   PubMedGoogle Scholar
• Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med. 2017;377(25):2500–2501. Cited in: PubMed; PMID 29262275.
   PubMed Web of Science ®Google Scholar
• Chalmers ZR, Connelly CF, Fabrizio D, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9(1):34. Cited in: PubMed; PMID 28420421.
   PubMed Web of Science ®Google Scholar
• Ratti M, Lampis A, Hahne JC, et al. Microsatellite instability in gastric cancer: molecular bases, clinical perspectives, and new treatment approaches. Cell Mol Life Sci. 2018;75(22):4151–4162. Cited in: PubMed; PMID 30173350.
   PubMed Web of Science ®Google Scholar
• Vilar E, Gruber SB. Microsatellite instability in colorectal cancer-the stable evidence. Nat Rev Clin Oncol. 2010;7(3):153–162. Cited in: PubMed; PMID 20142816.
   PubMed Web of Science ®Google Scholar
• Wang J, Yang J, Li D, et al. Technologies for targeting DNA methylation modifications: basic mechanism and potential application in cancer. Biochim Biophys Acta Rev Cancer. 2021;1875(1):188454. Cited in: PubMed; PMID 33075468.
   PubMed Web of Science ®Google Scholar
• Klutstein M, Nejman D, Greenfield R, et al. DNA methylation in cancer and aging. Cancer Res. 2016;76(12):3446–3450. Cited in: PubMed; PMID 27256564.
   PubMed Web of Science ®Google Scholar
• Fang M, Ou J, Hutchinson L, et al. The BRAF oncoprotein functions through the transcriptional repressor MAFG to mediate the CpG Island methylator phenotype. Mol Cell. 2014;55(6):904–915. Cited in: PubMed; PMID 25219500.
   PubMed Web of Science ®Google Scholar
• Keshet I, Schlesinger Y, Farkash S, et al. Evidence for an instructive mechanism of de novo methylation in cancer cells. Nat Genet. 2006;38(2):149–153. Cited in: PubMed; PMID 16444255.
   PubMed Web of Science ®Google Scholar
• Gajewski TF, Schreiber H, Fu Y-X. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013;14(10):1014–1022. Cited in: PubMed; PMID 24048123.
   PubMed Web of Science ®Google Scholar